Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lupin Limited ( (IN:LUPIN) ) has issued an update.
Lupin Limited has announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application for Lenalidomide Capsules, which are bioequivalent to Revlimid® Capsules by Bristol-Myers Squibb. These capsules, intended for treating multiple myeloma and transfusion-dependent anemia, will be manufactured at Lupin’s Pithampur facility in India. The approval marks a significant milestone for Lupin, potentially enhancing its market presence in the U.S. pharmaceutical sector, given the high annual sales of Lenalidomide Capsules in the U.S. market.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a presence in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds a strong market position in India and the U.S. across various therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The company operates 15 manufacturing sites and 7 research centers worldwide, employing over 24,000 professionals.
Average Trading Volume: 22,459
Technical Sentiment Signal: Strong Buy
Current Market Cap: 934.9B INR
Learn more about LUPIN stock on TipRanks’ Stock Analysis page.